Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that it received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) supporting the company's plans for an adaptive Phase 2 field study of TNX-4800, its long-acting anti-OspA monoclonal antibody candidate designed to prevent Lyme disease. This regulatory feedback is a significant milestone for Tonix as it advances the development of a potential seasonal immunopreventative against a tick-borne illness that affects hundreds of thousands of people in the United States each year.
The planned study is a randomized, placebo-controlled trial expected to enroll approximately 3,300 adults over two Lyme disease seasons. The primary objective is to evaluate the efficacy of TNX-4800 in preventing Lyme disease through six months after dosing, which would cover the typical peak transmission period. Manufacturing of the investigational product is on track for delivery to study sites in the first quarter of 2027, according to the company's announcement.
TNX-4800 is being developed as a seasonal immunopreventative administered as two subcutaneous injections three months apart. This dosing regimen is designed to provide protection throughout the U.S. Lyme disease season, which typically runs from spring through early fall. The long-acting nature of the monoclonal antibody could offer a novel approach to prophylaxis, potentially filling a gap in current prevention strategies that rely primarily on tick avoidance and early antibiotic treatment.
Lyme disease is the most common vector-borne illness in the United States, with the CDC estimating approximately 476,000 cases annually. Current preventive measures include personal protective behaviors and, in some cases, prophylactic antibiotics after a tick bite, but no vaccine is currently available for humans. An effective immunopreventative like TNX-4800 could significantly reduce the burden of this disease, which can cause debilitating long-term symptoms if not treated promptly.
The FDA's feedback comes at a pivotal time for Tonix, which is also building its commercial infrastructure around its recently approved fibromyalgia treatment, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new therapy for the condition in over 15 years. The company's CNS portfolio includes other promising candidates, such as TNX-2900 for Prader-Willi syndrome, and its immunology pipeline features TNX-4800 and TNX-1500, a CD40 ligand inhibitor for kidney transplant rejection prevention.
Investors and stakeholders may view this development as a positive signal for Tonix's strategic diversification into immunology, leveraging its expertise in developing biologics. The company's ability to secure FDA alignment on the study design de-risks the clinical pathway and underscores the potential of TNX-4800 to address a significant unmet medical need. As the study progresses, the outcomes will be closely watched by the medical community and public health officials alike, given the growing incidence of Lyme disease and the lack of a human vaccine.
For more information on Tonix Pharmaceuticals and its pipeline, visit the company's newsroom at https://ibn.fm/TNXP.
